腫瘍アブレーション市場レポート：技術、治療方法、用途、エンドユーザー、地域別、2024-2032

腫瘍アブレーションの世界市場規模は2023年に12億米ドルに達しました。今後、IMARC Groupは、2024年から2032年にかけて10.8%の成長率（CAGR）を示し、2032年までに31億米ドルに達すると予測しています。世界のがん罹患率の増加、医療技術の継続的な進歩、低侵襲がん治療に対する大衆の意識の高まりが、市場を推進している要因のいくつかです。

腫瘍アブレーションは、外科的切除を必要とせずに異常組織、特にがん性腫瘍を除去または破壊する医療処置です。高周波、レーザー、マイクロ波、冷凍アブレーションなど様々な技術を用いるこの低侵襲アプローチは、がん細胞を標的にし、正確に根絶します。この治療の特徴は、周囲の健康な組織へのダメージを最小限に抑えることで、回復時間を短縮し、患者の生活の質を向上させることです。これらの治療は通常、超音波、CTスキャン、MRIなどの画像技術によって誘導され、より精度の高いリアルタイムデータを提供します。

腫瘍アブレーションの世界市場は、主に世界のがん罹患率の増加によって牽引されています。これに伴い、医療技術の継続的な進歩が市場に弾みをつけています。さらに、低侵襲のがん治療に対する大衆の意識の高まりが、市場の重要な成長促進要因として作用しています。これに加えて、がんに罹患しやすい高齢化社会が、腫瘍アブレーション療法への投資の増加をもたらしています。これに加えて、外科的合併症の減少に重点を置くヘルスケアシステムが、市場に有利な機会を生み出しています。また、精密医療の出現も市場にプラスの影響を与えています。特に先進諸国では、医療費の増加が市場をさらに後押ししています。市場に貢献しているその他の要因としては、医療ツーリズムの増加、高度医療施設へのアクセスの向上、広範な研究開発（R&D）活動などが挙げられます。

腫瘍アブレーションの市場動向と促進要因：

患者中心のアプローチの台頭

現代のヘルスケアでは、患者一人ひとりのニーズや状況に合わせて治療を行う個別化医療がますます重視されるようになっています。このような患者中心主義へのシフトは、腫瘍アブレーション市場を大きく変えています。年齢、病歴、遺伝的素因など、患者のさまざまな要因を考慮して治療法を設計することで、ヘルスケアプロバイダーは高度に的を絞った効果的な治療計画を立てています。このような個別化アプローチは、腫瘍の性質が不均一なため、しばしば独自の治療反応を示すがん患者にとって特に重要です。データ解析、ゲノミクス、個別化された病歴を活用することで、ヘルスケアプロバイダーは個々の患者にとって最も適切な腫瘍アブレーション療法を選択することができます。このような高度なパーソナライゼーションは、治療効果を向上させるだけでなく、患者の満足度と信頼性を高め、ひいては腫瘍アブレーション療法を選択する人を増やすことにつながります。

デジタル技術の統合が進む

人工知能（AI）、機械学習、ビッグデータ解析などのデジタル技術のヘルスケアシステムへの統合は、市場拡大の原動力となっています。これらの技術により、ヘルスケアプロバイダーは、患者の履歴、リアルタイムのモニタリング、予測モデリングなどの包括的なデータ分析に基づいて、より多くの情報に基づいた意思決定を行うことができます。こうしたデジタル技術の進歩は、患者の診断や治療計画だけにとどまらないです。ヘルスケアシステムの運用面にも及んでおり、管理の合理化、諸経費の削減、ケア提供の効率化を実現しています。デジタル技術は、異なる診療科間、あるいは異なるヘルスケア施設間でのリアルタイムな情報共有を容易にし、患者のケアを調整し、必要に応じて治療を適応させることを容易にします。このような業務効率の向上は、患者の転帰を改善するだけでなく、腫瘍アブレーション療法の導入をヘルスケアシステムにとってより経済的に実行可能なものにします。

主要企業間の提携と買収の増加

官民双方からの投資の流入は、市場の形成に重要な役割を果たしています。政府補助金、助成金、公的資金は、ヘルスケア分野における研究開発の基礎的な支援となります。これらの資金により、医療研究者は、市場の実現可能性という当面のプレッシャーを受けることなく、腫瘍アブレーションの革新的な技術や技法を探求することができます。他方、民間投資は、しばしばベンチャーキャピタルという形で、これらの新技術の商業化プロセスを加速させる。公的資金と民間資金の利害が一致することで、学術的な厳密さと市場志向のアプローチが融合し、画期的なイノベーションが生まれることが多いです。例えば、公的資金が新しい腫瘍アブレーション技術の開発に必要な初期段階の研究を支援する一方、民間投資はそれを市場に出すために必要な臨床試験やマーケティングを促進することができます。この二重投資の流れは、技術革新のペースを加速させるだけでなく、より強固でダイナミックな市場情勢を生み出し、競争力を促進し、結果として市場成長を促進します。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査目的
• 利害関係者
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要産業動向

第5章 腫瘍アブレーションの世界市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場内訳：技術別
• 市場内訳：治療モード別
• 市場内訳：用途別
• 市場内訳：エンドユーザー別
• 市場内訳：地域別
• 市場予測

第6章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第9章 市場内訳：技術別

• 高周波（RF）アブレーション
  • 市場動向
  • 市場予測
• マイクロ波アブレーション
  • 市場動向
  • 市場予測
• クライオアブレーション
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第10章 市場内訳：治療方法別

• 経皮的アブレーション
  • 市場動向
  • 市場予測
• 腹腔鏡下アブレーション
  • 市場動向
  • 市場予測
• 外科的アブレーション
  • 市場動向
  • 市場予測

第11章 市場内訳：用途別

• 肝臓がん
  • 市場動向
  • 市場予測
• 肺がん
  • 市場動向
  • 市場予測
• 腎臓がん
  • 市場動向
  • 市場予測
• 骨転移
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第12章 市場内訳：エンドユーザー別

• 病院
  • 市場動向
  • 市場予測
• がん専門クリニック
  • 市場動向
  • 市場予測
• その他
  • 市場動向
  • 市場予測

第13章 市場内訳：地域別

• 北米
  • 市場動向
  • 市場予測
• 欧州
  • 市場動向
  • 市場予測
• アジア太平洋
  • 市場動向
  • 市場予測
• 中東・アフリカ地域
  • 市場動向
  • 市場予測
• ラテンアメリカ
  • 市場動向
  • 市場予測

第14章 価格分析

第15章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Medtronic Public Limited Company
  • AngioDynamics Inc.
  • HealthTronics Inc.
  • NeuWave Medical, Inc.
  • INTIO Inc.
  • Galil Medical Ltd
  • Boston Scientific Corporation
  • SonaCare Medical LLC
  • EDAP TMS S.A.
  • Erbe Elektromedizin GmbH
  • IceCure Medical Ltd
  • MISONIX Inc.
  • Endocare Inc.
  • CooperSurgical Inc.
  • B V M Meditech Pvt

List of Figures

• Figure 1: Global: Tumor Ablation Market: Major Drivers and Challenges
• Figure 2: Global: Tumor Ablation Market: Sales Value (in Million US$), 2018-2023
• Figure 3: Global: Tumor Ablation Market: Breakup by Technology (in %), 2023
• Figure 4: Global: Tumor Ablation Market: Breakup by Mode of Treatment (in %), 2023
• Figure 5: Global: Tumor Ablation Market: Breakup by Mode of Application (in %), 2023
• Figure 6: Global: Tumor Ablation Market: Breakup by End-User (in %), 2023
• Figure 7: Global: Tumor Ablation Market: Breakup by Region (in %), 2023
• Figure 8: Global: Tumor Ablation Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 9: Global: Tumor Ablation Industry: SWOT Analysis
• Figure 10: Global: Tumor Ablation Industry: Value Chain Analysis
• Figure 11: Global: Tumor Ablation Industry: Porter's Five Forces Analysis
• Figure 12: Global: Tumor Ablation (Radiofrequency Ablation) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 13: Global: Tumor Ablation (Radiofrequency Ablation) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 14: Global: Tumor Ablation (Microwave Ablation) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 15: Global: Tumor Ablation (Microwave Ablation) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 16: Global: Tumor Ablation (Cryoablation) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 17: Global: Tumor Ablation (Cryoablation) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 18: Global: Tumor Ablation (Other Technologies) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 19: Global: Tumor Ablation (Other Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 20: Global: Tumor Ablation (Percutaneous Ablation) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 21: Global: Tumor Ablation (Percutaneous Ablation) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 22: Global: Tumor Ablation (Laparoscopic Ablation) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 23: Global: Tumor Ablation (Laparoscopic Ablation) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 24: Global: Tumor Ablation (Surgical Ablation) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 25: Global: Tumor Ablation (Surgical Ablation) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 26: Global: Tumor Ablation (Liver Cancer) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 27: Global: Tumor Ablation (Liver Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 28: Global: Tumor Ablation (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 29: Global: Tumor Ablation (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 30: Global: Tumor Ablation (Kidney Cancer) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 31: Global: Tumor Ablation (Kidney Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 32: Global: Tumor Ablation (Bone Metastasis) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 33: Global: Tumor Ablation (Bone Metastasis) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 34: Global: Tumor Ablation (Other Mode of Applications) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 35: Global: Tumor Ablation (Other Mode of Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 36: Global: Tumor Ablation (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 37: Global: Tumor Ablation (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 38: Global: Tumor Ablation (Cancer Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 39: Global: Tumor Ablation (Cancer Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 40: Global: Tumor Ablation (Other End-Users) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 41: Global: Tumor Ablation (Other End-Users) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 42: North America: Tumor Ablation Market: Sales Value (in Million US$), 2018 & 2023
• Figure 43: North America: Tumor Ablation Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 44: Europe: Tumor Ablation Market: Sales Value (in Million US$), 2018 & 2023
• Figure 45: Europe: Tumor Ablation Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 46: Asia Pacific: Tumor Ablation Market: Sales Value (in Million US$), 2018 & 2023
• Figure 47: Asia Pacific: Tumor Ablation Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 48: Middle East and Africa: Tumor Ablation Market: Sales Value (in Million US$), 2018 & 2023
• Figure 49: Middle East and Africa: Tumor Ablation Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 50: Latin America: Tumor Ablation Market: Sales Value (in Million US$), 2018 & 2023
• Figure 51: Latin America: Tumor Ablation Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

• Table 1: Global: Tumor Ablation Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Tumor Ablation Market Forecast: Breakup by Technology (in Million US$), 2024-2032
• Table 3: Global: Tumor Ablation Market Forecast: Breakup by Mode of Treatment (in Million US$), 2024-2032
• Table 4: Global: Tumor Ablation Market Forecast: Breakup by Mode of Application (in Million US$), 2024-2032
• Table 5: Global: Tumor Ablation Market Forecast: Breakup by End-User (in Million US$), 2024-2032
• Table 6: Global: Tumor Ablation Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 7: Global: Tumor Ablation Market Structure
• Table 8: Global: Tumor Ablation Market: Key Players

The global tumor ablation market size reached US$ 1,200 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 3,100 Million by 2032, exhibiting a growth rate (CAGR) of 10.8% during 2024-2032. The increasing incidence of cancer cases across the globe, continual advancements in medical technology, and growing awareness about minimally invasive cancer treatments among the masses represent some of the factors that are propelling the market.

Tumor ablation is a medical procedure that involves the removal or destruction of abnormal tissue, particularly cancerous tumors, without the need for surgical excision. Employing various techniques such as radiofrequency, laser, microwave, or cryoablation, this minimally invasive approach targets cancerous cells and eradicates them with precision. The process is characterized by its ability to minimize damage to surrounding healthy tissues, thereby reducing recovery time and improving the patient's quality of life. These treatments are typically guided by imaging technologies such as ultrasound, CT scans, or MRI, which provide real-time data for higher accuracy.

The global market for tumor ablation is primarily driven by the increasing incidence of cancer cases across the globe. In line with this, continual advancements in medical technology are providing an impetus to the market. Moreover, the growing awareness about minimally invasive cancer treatments among the masses is acting as a significant growth-inducing factor for the market. In addition to this, the aging population, which is more susceptible to cancer, is resulting in higher investment in tumor ablation therapies. Besides this, healthcare systems' focus on reducing surgical complications is creating lucrative opportunities in the market. Also, the emergence of precision medicine is positively impacting the market. The market is further propelled by increased healthcare expenditure, particularly in developed countries. Some of the other factors contributing to the market include the rise of medical tourism, greater accessibility to advanced healthcare facilities, and extensive research and development (R&D) activities.

Tumor Ablation Market Trends/Drivers:

Rise in the patient-centric approaches

The modern healthcare landscape is increasingly focusing on personalized care, with treatments being tailored to meet the unique needs and circumstances of each patient. This shift towards patient-centricity has been a game-changer for the tumor ablation market. By designing therapies that consider various patient factors such as age, medical history, and genetic predispositions, healthcare providers are creating highly targeted and effective treatment plans. This personalized approach is particularly important for cancer patients, who often have unique therapeutic responses due to the heterogeneous nature of tumors. By leveraging data analytics, genomics, and personalized medical histories, healthcare providers are better equipped to select the most appropriate tumor ablation therapy for individual patients. This higher degree of personalization not only improves the efficacy of treatments but also increases patient satisfaction and trust, which in turn encourages more people to opt for tumor ablation therapies.

Increasing integration of digital technologies

The integration of digital technologies such as artificial intelligence (AI), machine learning, and big data analytics into healthcare systems is a driving force behind the expansion of the market. These technologies enable healthcare providers to make more informed decisions based on comprehensive data analysis, including patient histories, real-time monitoring, and predictive modeling. These digital advancements are not just limited to patient diagnosis and treatment plans. They also extend to the operational aspects of healthcare systems, streamlining the administration, reducing overhead costs, and improving the efficiency of delivering care. Digital technologies facilitate the real-time sharing of information across different departments or even different healthcare facilities, making it easier to coordinate patient care and adapt treatments as required. This enhanced operational efficiency not only improves patient outcomes but also makes the adoption of tumor ablation therapies more financially viable for healthcare systems.

Rising partnerships and acquisitions amongst key players

The influx of investment from both public and private sectors plays a critical role in shaping the market. Government grants, subsidies, and public funding serve as foundational support for research and development in the healthcare sector. These funds enable medical researchers to explore innovative techniques and technologies in tumor ablation without the immediate pressure of market viability. On the other side, private investment, often in the form of venture capital, accelerates the commercialization process of these new technologies. The alignment of public and private financial interests can often yield breakthrough innovations, as it brings together academic rigor and market-oriented approaches. For instance, public funding can support the early-stage research needed to develop a novel tumor ablation technique, while private investment can facilitate the clinical trials and marketing required to bring it to market. This dual investment stream not only accelerates the pace of innovation but also creates a more robust and dynamic market landscape, fostering competitiveness and, consequently, driving market growth.

Tumor Ablation Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global tumor ablation market report, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on technology, mode of treatment, mode of application and end-user.

Breakup by Technology:

Radiofrequency (RF) Ablation

Microwave Ablation

Cryoablation

Others

Radiofrequency (RF) ablation represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the technology. This includes radiofrequency (RF) ablation, microwave ablation, cryoablation and others. According to the report, radiofrequency (RF) ablation represented the largest segment.

The radiofrequency (RF) ablation segment is primarily driven by its high efficacy rates, shorter procedure times, and minimally invasive nature. Technological advancements have made RF ablation more precise and safe, attracting physicians and patients alike. Moreover, the cost-effectiveness compared to traditional surgical methods has further boosted its adoption. Reimbursement policies have also been favorable, encouraging the use of RF ablation for tumor treatments. Overall, these factors contribute to its major share in the global tumor ablation market.

On the other hand, microwave, cryoablation, and other methods are becoming increasingly popular due to advancements in technology. They offer alternatives to RF ablation but tend to be more expensive and less covered by insurance. Their adoption is also limited by the need for specialized training for healthcare providers. Despite these challenges, they hold a minor but growing segment in the market.

Breakup by Mode of Treatment:

Percutaneous Ablation

Laparoscopic Ablation

Surgical Ablation

Surgical ablation accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the mode of treatment. This includes percutaneous ablation, laparoscopic ablation, and surgical ablation. According to the report, surgical ablation represented the largest segment.

Surgical ablation remains a conventional and highly effective approach for treating various types of tumors. It is often recommended for cases where the tumor is large or not amenable to minimally invasive techniques. Given the invasive nature, surgical ablation usually necessitates longer hospital stays and recovery periods, which can be a downside. However, its proven efficacy and completeness in tumor removal secure its significant role in the global market.

On the other hand, percutaneous and laparoscopic methods are minimally invasive and preferred for small to medium-sized tumors. These techniques are cost-effective but require specialized equipment and training. Their minor market share is partly due to limitations in treating complex or larger tumors. Nonetheless, they remain valuable options in the broader scope of ablation methods.

Breakup by Mode of Application:

Liver Cancer

Lung Cancer

Kidney Cancer

Bone Metastasis

Others

Liver cancer represents the largest market segment

The report has provided a detailed breakup and analysis of the market based on the mode of application. This includes liver cancer, lung cancer, kidney cancer, bone metastasis and others. According to the report, liver cancer represented the largest segment.

Liver cancer dominates the global tumor ablation market, largely due to the high incidence and mortality rates associated with this disease. The ablation techniques offer a viable treatment option for early-stage liver cancer, where surgical removal may not be feasible. As liver cancer is often diagnosed at an advanced stage, ablation techniques are viewed as essential palliative treatments. High adoption rates and the emphasis on research for liver cancer ablation contribute to its significant market share.

On the other hand, the other segments including lung, kidney, and bone metastasis are gradually gaining traction due to technological improvements. These cancers are typically treated with other therapies, but ablation is becoming a more common secondary or complementary option. Limitations in insurance coverage and less substantial clinical evidence compared to major segments hold back their market share.

Breakup by End-User:

Hospitals

Cancer Specialty Clinics

Others

Hospitals accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the end-user. This includes hospitals, cancer specialty clinics and others. According to the report, hospitals represented the largest segment.

Hospitals constitute a significant share of the market due to their comprehensive healthcare services and accessibility to a wide patient demographic. They have the financial capability to invest in advanced ablation technologies, and their multidisciplinary teams can offer a variety of treatment options. With the increasing incidence of cancer, hospitals continue to adopt tumor ablation techniques, solidifying their role in the global market.

On the other hand, specialized cancer clinics focus exclusively on cancer treatment, making them ideal centers for advanced ablation therapies. These clinics often have cutting-edge technologies and highly skilled specialists, which makes them attractive for patients seeking specialized care. However, these centers may not be as widespread as hospitals, limiting their accessibility. Their specific focus and expertise, though, contribute to an increasing share in the global market.

Breakup by Region:

North America

Europe

Asia Pacific

Middle East and Africa

Latin America

North America exhibits a clear dominance, accounting for the largest tumor ablation market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America; Europe; Asia Pacific; the Middle East and Africa; and Latin America. According to the report, North America accounted for the largest market share.

North America holds a dominant position in the global market, driven by a number of factors including high healthcare expenditure, advanced medical technologies, and a robust healthcare infrastructure. The region also benefits from favorable reimbursement policies, which make various ablation treatments more accessible to patients. Furthermore, the prevalence of cancer is relatively high in North America, leading to greater demand for effective treatment methods such as tumor ablation.

Research and development (R&D) activities in the region are vigorous, further propelling the adoption of new and improved ablation techniques. Pharmaceutical and medical device companies in North America also contribute to market growth by investing in research, thereby enhancing the technology and its applications. The presence of key market players headquartered in the region adds to the competitive advantage. Educational campaigns and patient awareness programs are also more prevalent here, aiding in early diagnosis and treatment.

Competitive Landscape:

Leaders in the global tumor ablation market are dedicating resources to clinical trials and research to improve the efficacy and safety of their solutions. They are also focusing on developing minimally invasive techniques to cater to patient comfort and faster recovery. Telehealth integrations are in progress to facilitate remote consultations, thereby increasing the adoption rate of their products. Regulatory approvals are a key focus, and as such, these entities are navigating complex compliance landscapes both domestically and internationally. To maintain a competitive edge, alliances with healthcare providers and medical institutions, and implementation of robust after-sales support and training programs are being formed. Furthermore, educational programs for healthcare professionals are being launched to foster proper utilization of the technology.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Medtronic Public Limited Company

AngioDynamics Inc.

HealthTronics Inc.

NeuWave Medical, Inc.

INTIO Inc.

Galil Medical Ltd

Boston Scientific Corporation

SonaCare Medical LLC

EDAP TMS S.A.

Erbe Elektromedizin GmbH

IceCure Medical Ltd

MISONIX Inc.

Endocare Inc.

CooperSurgical Inc.

B V M Meditech Pvt

Recent Developments:

In August 2023, Medtronic Public Limited Company received CE (Conformite Europeenne) Mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator (SCS). It is the first Medtronic SCS device to offer a closed-loop feature that senses each person's unique biological signals and adjusts stimulation moment to moment, as needed, to keep therapy in harmony with the motions of daily life.

In March 2023, AngioDynamics announced several new partnerships with AddLife in the UK, Ireland & Nordics markets. The new distribution arrangements will see Healthcare 21, part of the AddLife Group, distribute AngioDynamics' oncology and surgical product portfolio in the UK and Ireland, and Mediplast in the Nordics.

In August 2023, Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month results from the pivotal ADVENT clinical trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields selectively ablate heart tissue in patients with atrial fibrillation (AF). The study is the first randomized clinical trial to directly compare the efficacy and safety of the FARAPULSE PFA System against standard-of-care ablation - either radiofrequency or cryoablation - for the treatment of patients with paroxysmal, or intermittent, AF.

Key Questions Answered in This Report

• 1. What was the size of the global tumor ablation market in 2023?
• 2. What is the expected growth rate of the global tumor ablation market during 2024-2032?
• 3. What has been the impact of COVID-19 on the global tumor ablation market?
• 4. What are the key factors driving the global tumor ablation market?
• 5. What is the breakup of the global tumor ablation market based on the technology?
• 6. What is the breakup of the global tumor ablation market based on the mode of treatment?
• 7. What is the breakup of the global tumor ablation market based on mode of application?
• 8. What is the breakup of the global tumor ablation market based on the end-user?
• 9. What are the key regions in the global tumor ablation market?
• 10. Who are the key players/companies in the global tumor ablation market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Tumor Ablation Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Breakup by Technology
• 5.5 Market Breakup by Mode of Treatment
• 5.6 Market Breakup by Mode of Application
• 5.7 Market Breakup by End-User
• 5.8 Market Breakup by Region
• 5.9 Market Forecast

6 SWOT Analysis

• 6.1 Overview
• 6.2 Strengths
• 6.3 Weaknesses
• 6.4 Opportunities
• 6.5 Threats

7 Value Chain Analysis

8 Porter's Five Forces Analysis

• 8.1 Overview
• 8.2 Bargaining Power of Buyers
• 8.3 Bargaining Power of Suppliers
• 8.4 Degree of Competition
• 8.5 Threat of New Entrants
• 8.6 Threat of Substitutes

9 Market Breakup by Technology

• 9.1 Radiofrequency (RF) Ablation
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Microwave Ablation
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Cryoablation
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast
• 9.4 Others
  • 9.4.1 Market Trends
  • 9.4.2 Market Forecast

10 Market Breakup by Mode of Treatment

• 10.1 Percutaneous Ablation
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Laparoscopic Ablation
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Surgical Ablation
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast

11 Market Breakup by Mode of Application

• 11.1 Liver Cancer
  • 11.1.1 Market Trends
  • 11.1.2 Market Forecast
• 11.2 Lung Cancer
  • 11.2.1 Market Trends
  • 11.2.2 Market Forecast
• 11.3 Kidney Cancer
  • 11.3.1 Market Trends
  • 11.3.2 Market Forecast
• 11.4 Bone Metastasis
  • 11.4.1 Market Trends
  • 11.4.2 Market Forecast
• 11.5 Others
  • 11.5.1 Market Trends
  • 11.5.2 Market Forecast

12 Market Breakup by End-User

• 12.1 Hospitals
  • 12.1.1 Market Trends
  • 12.1.2 Market Forecast
• 12.2 Cancer Specialty Clinics
  • 12.2.1 Market Trends
  • 12.2.2 Market Forecast
• 12.3 Others
  • 12.3.1 Market Trends
  • 12.3.2 Market Forecast

13 Market Breakup by Region

• 13.1 North America
  • 13.1.1 Market Trends
  • 13.1.2 Market Forecast
• 13.2 Europe
  • 13.2.1 Market Trends
  • 13.2.2 Market Forecast
• 13.3 Asia Pacific
  • 13.3.1 Market Trends
  • 13.3.2 Market Forecast
• 13.4 Middle East and Africa
  • 13.4.1 Market Trends
  • 13.4.2 Market Forecast
• 13.5 Latin America
  • 13.5.1 Market Trends
  • 13.5.2 Market Forecast

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Medtronic Public Limited Company
  • 15.3.2 AngioDynamics Inc.
  • 15.3.3 HealthTronics Inc.
  • 15.3.4 NeuWave Medical, Inc.
  • 15.3.5 INTIO Inc.
  • 15.3.6 Galil Medical Ltd
  • 15.3.7 Boston Scientific Corporation
  • 15.3.8 SonaCare Medical LLC
  • 15.3.9 EDAP TMS S.A.
  • 15.3.10 Erbe Elektromedizin GmbH
  • 15.3.11 IceCure Medical Ltd
  • 15.3.12 MISONIX Inc.
  • 15.3.13 Endocare Inc.
  • 15.3.14 CooperSurgical Inc.
  • 15.3.15 B V M Meditech Pvt